Black Diamond Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
10b5-1 Plans
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2024, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
On October 9, 2024, Fang Ni, Pharm.D., our former Chief Business Officer and Chief Financial Officer, terminated a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan). The Ni 10b5-1 Plan was adopted on June 29, 2024, had a term of one year and provided for the sale of up to 40,470 shares of common stock pursuant to its terms. No shares have been sold under the Ni 10b5-1 Plan as of the date of its termination.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.